Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Filings indexed 477 across all filing types
Latest filing 2022-08-13 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Newspaper Advertisements
Regulatory Filings
2022-08-13 English
Investor Presentation
Regulatory Filings
2022-08-13 English
General updates
Regulatory Filings
2022-08-12 English
Monitoring Agency Report
Regulatory Filings
2022-08-12 English
Outcome of Board Meeting
Regulatory Filings
2022-08-12 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 90% confidence The document is an invitation to an earnings call for Q1 FY23, mentioning the date, time, participants, and access numbers. It does not contain actual financial results or detailed analysis but is a notice for a conference call discussing financial performance. Therefore, it fits the category of a Call Transcript (CT) announcement or invitation rather than the transcript itself. However, since it is an invitation to the call, not the transcript, it is best classified as a Call Transcript (CT) type as per the closest relevant category for earnings call content.
2022-08-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.